Current priorities:
- Beta cell regeneration
- Closed loop, pump, and CGM technology
- C-peptide and glucose variability - residual insulin production
- Glucagon and its role in type 1 diabetes
- Hormones in type 1 diabetes
- Insulin resistance in type 1 diabetes
- Mental health and type 1 diabetes
- Prevention and population screening
- Patient Reported Outcome Measures (PROMs) and quality of life
Chair: Professor Colin Dayan, Cardiff University
Professor Dayan has a long established interest in the underlying biology of type 1 diabetes and is currently conducting early phase clinical trials in the development of type 1 diabetes immunotherapy.
Who's involved?
- Associate Professor Ramzi Ajjan, Deputy Chair
- Becki Millar
- David Dupont
- Hannah Sutton
- Alex Clarke
- Sarah Jarrett
- Andrew Brasher
- Elaine Hibbert-Jones
- Dr Ildem Akerman
- Dr James Cantley
- James Shaw
- Dr Jill Carlton
- Professor Parth Narendran
If you would like to share your views with the group on where research into prevention, targets and therapies for type 1 diabetes should be focused, please get in touch: drsgs@diabetes.org.uk.